pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Immunology · news · pharmadog
← back to Immunology
News · Immunology
695
stories
11d
Berlin Seeds Recalls Alfalfa Sprouting Seed Because of Possible Health Risk
fda recalls
11d
Enveda, an AI drugmaker, banks $311M in venture funding
biopharma dive
12d
Roche, Ionis RNA drug scores in kidney disease study
biopharma dive
12d
Kyverna ‘resetting conversation’ with 1-year miv-cel data as autoimmune CAR-T peers hit safety snags
fiercebiotech
12d
Immunovant ditches lupus for multi-hyphenate inflammatory drug after mid-stage miss
biospace
12d
Roivant reports Phase 2b lupus failure for an FcRn drug
endpoints
12d
Amgen asset from $27.8B Horizon buy scores in Phase 3 Sjögren's study
biospace
12d
Trump's Department of War bets $47M on Flagship biotechs to develop countermeasures
fiercebiotech
12d
Roche’s phase 3 win tees up fight with Novartis for blockbuster kidney disease market
fiercebiotech
12d
Amgen reports a Phase 3 win with Sjögren’s drug candidate
biopharma dive
12d
Opinion: Former FDA commissioners: Heidi Overton has an opportunity to strengthen the FDA
stat
13d
Celldex sinks as safety concerns cloud immune drug results
biopharma dive
13d
Lilly presents early data supporting GLP-1/GIP candidate's potential in depression, alcohol use disorder
biospace
13d
2026 IPO blitz continues with 4 new biotech filings
biospace
13d
An orexin drug’s ‘proof-of-concept’ in ADHD; Cue’s ‘unwarranted’ share slide
biopharma dive
13d
Amgen’s Horizon-acquired fusion protein eases Sjögren's severity in ph. 3 win
fiercebiotech
13d
Lexeo takes up the Mantle in $8M acquisition for Friedreich ataxia assets
fiercebiotech
13d
Opinion: The science on relieving cancer symptoms is clear. Why isn’t insurance paying?
stat
14d
Boehringer, Envisagenics sign $1B multi-target oncology collaboration
fiercebiotech
14d
Novo struggles to appease restive investors with consumer plans, blockbuster ambitions
fiercebiotech
14d
Cue Biopharma's potential Xolair challenger passes Phase 2 chronic hives trial
endpoints
14d
Skeptical about modern medicine? I know the feeling — and want to listen
stat
14d
Retension and Lilly-backed TRex Bio both set out plans to join biotech IPO stampede
fiercebiotech
14d
Citing Replimune approval, experts say localized cancer meds could redefine care
biospace
14d
STAT+: Radiopharma companies merge after one receives surprise FDA rejection
stat
16d
China plans to transform biotech sector into $522B powerhouse by 2030
biospace
17d
Electra lights up with $350M IPO for pivotal immune-disease drug development
biospace
17d
STAT+: Roche expands its Boston footprint with new research center
stat
17d
Inflammation biotech Electra charges up with $350M from upsized IPO
fiercebiotech
17d
Electra amasses $350M in biotech’s latest big IPO
biopharma dive
← prev
page 4 of 24
next →
